ArticleAmerican journal of translational research2025
Intra-articular sodium hyaluronate, compound betamethasone, and ropivacaine combined with arthroscopic debridement in patients with knee osteoarthritis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy of sodium hyaluronate (SH), compound betamethasone (BT), and ropivacaine (Rop) in combination with arthroscopic debridement (AD) for the treatment of knee osteoarthritis (KOA).
methodsA retrospective analysis was conducted on 107 KOA patients treated at Shantou Central Hospital l, including 52 patients in the control group who received AD alone and 55 patients in the observation group who additionally received intra-articular SH, compound BT, and Rop. Treatment efficacy, pain levels, knee joint function, lower limb motor function, serum inflammatory markers, quality of life, and sleep quality were assessed and compared between the two groups. Univariate and multivariate logistic regression analyses were performed to identify factors influencing treatment outcomes.
resultsThe observation group showed significantly better outcomes than the control group in terms of overall treatment efficacy, pain relief, improvement in joint and lower limb function, reduction in inflammatory markers, and enhancement of both sleep quality and overall quality of life. Prolonged disease duration was identified as an independent risk factor for poor treatment outcomes.
conclusionThe combination of SH, compound BT, and Rop with AD offers significant clinical advantages in the management of KOA, supporting its broader adoption in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.